Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
Currie
Craig J
CJ
McEwan
Phil
P
Poole
Chris
C
Valentine
William J
WJ
Palmer
Andrew J
AJ
Lammert
Morten
M
Nicklasson
Lars
L
Foos
Volker
V
Roze
Stéphane
S
D061265:Biphasic Insulins; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017048:Health Care Costs; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D061267:Insulin Aspart; D000069036:Insulin Glargine; D007336:Insulin, Isophane; D049528:Insulin, Long-Acting; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D061265:Biphasic Insulins; D007328:Insulin; D049528:Insulin, Long-Acting; C557564:insulin aspart, insulin aspart protamine drug combination 30:70; D000069036:Insulin Glargine; D007336:Insulin, Isophane; D061267:Insulin Aspart